title: [Safety of nicotine addiction treatment].
abstract: Not all smoking addicts can succeed in quitting smoking with willpower only. These people may use nicotine replacement therapy (patches, gums, lozenges, sublingual tablets, inhalers), medicines (bupropion, varenicline and cytisine) and psychological aid. Each drug, besides its therapeutic effect, creates the risk of adverse reactions which number and severity is not always accepted by the patient. The aim of the study was to analyze adverse effects of bupropion, varenicline and cytisine formulations reported by patients. From July 2011 to June 2013 Regional Centre for Monitoring Adverse Drug Reactions (Department of Clinical Pharmacology, Department of Cardiology, Poznan University of Medical Sciences) recorded 32 suspected adverse reactions to the use of drugs for the treatment of nicotine addiction (12 after the preparation of cytisine and varenicline, 8 after preparations of bupropion). High determination caused that none of the patients withdrew from the therapy because of adverse effects.
authors: Zaklad Farmakologii Klinicznej Katedra Kardiologii Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
authors: Katarzyna
authors: K
authors: Korzeniowska
authors: Zaklad Farmakologii Klinicznej Katedra Kardiologii Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
authors: Artur
authors: A
authors: Cieślewicz
authors: Zaklad Farmakologii Klinicznej Katedra Kardiologii Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
authors: Anna
authors: A
authors: Jabłecka
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000328:Adult; D000470:Alkaloids / Q000009:adverse effects*; D001392:Azocines / Q000009:adverse effects; D001552:Benzazepines / Q000009:adverse effects*; D001887:Boredom; D016642:Bupropion / Q000009:adverse effects*; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000819:agonists / Q000037:antagonists & inhibitors; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011807:Quinolizines / Q000009:adverse effects; D011810:Quinoxalines / Q000009:adverse effects*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D000068580:Varenicline; D014987:Xerostomia / Q000139:chemically induced; D000093843:Quinolizidine Alkaloids
chemical_list: D000470:Alkaloids; D001392:Azocines; D001552:Benzazepines; D016642:Bupropion; D009538:Nicotine; D011807:Quinolizines; D011810:Quinoxalines; D000068580:Varenicline; C004712:cytisine; D000093843:Quinolizidine Alkaloids